Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy

Published:2022-05-31 Issue:7 Volume:19 Page:2429-2440
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Behl Akanksha¹,Sarwalia Parul²,Kumar Sushil²,Behera Chittaranjan³,Mintoo Mubashir Javed⁴,Datta Tirtha Kumar²,Gupta Prem N.³,Chhillar Anil K.¹^ORCID

Affiliation:

1. Centre for Biotechnology, Maharshi Dayanand University, Rohtak, Haryana 124 001, India

2. Animal Biotechnology Centre, ICAR-National Dairy Research Institute, Karnal, Haryana 132001, India

3. PK-PD Tox and Formulation Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, India

4. Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, India

Funder

Department of Science and Technology, Ministry of Science and Technology

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.2c00175

Reference54 articles.

1. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

2. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

3. Global cancer statistics

4. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

5. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabrication, characterization, and optimization of core–shell electrospun nanofibers for simultaneous sustained delivery of metformin and glibenclamide in type II diabetes treatment;Polymer Bulletin;2024-06-07

2. Nanotherapeutics targeting autophagy regulation for improved cancer therapy;Acta Pharmaceutica Sinica B;2024-06

3. Gemcitabine Hydrochloride Drug-Delivery System Based on Folic Acid/Gold Nanoparticle Co-Modified Red Blood Cells for Breast Cancer Treatment;ACS Applied Nano Materials;2024-04-29

4. A Cathepsin B-Sensitive Gemcitabine Prodrug for Enhanced Pancreatic Cancer Therapy;Journal of Pharmaceutical Sciences;2024-03

5. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches;Environmental Research;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3